Court Denies Free "Weight Loss Pen" to Obese Resident in Araçatuba
The São Paulo Court of Justice (TJSP) has denied a free supply of "weight loss pens" to a resident of Araçatuba, São Paulo, who suffers from obesity and related health conditions. The 12th Public Law Chamber of the TJSP upheld a previous decision from the Public Treasury Court, refusing to provide the injectable medication, semaglutide, at no cost to the woman. Although the drug is registered with the National Health Surveillance Agency (Anvisa), it is not included in the list of medications covered by the Unified Health System (SUS), according to the lawsuit. The resident had argued that she needed the medication for weight reduction. However, the rapporteur of the appeal, Judge Edson Ferreira, cited a negative technical opinion from the Judiciary's Technical Support Unit (NatJus). This unit concluded that there is no robust clinical evidence demonstrating a crucial advantage of semaglutide for obesity treatment compared to therapies already available through the public health system. Despite the patient's comorbidities, including type 2 diabetes mellitus, arterial hypertension, and heart failure, the court determined that the medical report submitted did not prove that this specific medication was the only viable option. The court's decision was unanimous, with judges Souza Meirelles and Jayme de Oliveira concurring with the rapporteur.
This judicial decision highlights the tension between patient access to novel, potentially effective treatments and the fiscal constraints and established protocols of public healthcare systems. While semaglutide has shown promise, the court's reliance on NatJus's assessment underscores the need for rigorous, comparative clinical data to justify inclusion in public formularies, especially when alternative treatments exist. The ruling reflects a systemic challenge in balancing innovation with equitable resource allocation, prompting consideration of how evidence-based efficacy, cost-effectiveness, and patient-specific needs are weighed in healthcare policy. Future healthcare models may need to incorporate more dynamic mechanisms for evaluating and integrating emerging therapies, ensuring both patient well-being and system sustainability in the long term.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.